Ipamorelin vs CJC-1295 (No DAC)
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.
Also: CJC-1295 DAC, CJC-1295 no DAC
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29). The name covers two different products. CJC-1295 with DAC (Drug Affinity Complex) binds blood albumin, which stretches its half-life to roughly 6 to 8 days and raises GH and IGF-I for days from a single injection; this is the version ConjuChem took to Phase II before abandoning it, and the version the human data are about. CJC-1295 without DAC (Modified GRF 1-29, the form this page is named for) lacks the albumin tether and is much shorter acting, though its human half-life has not been formally published. Neither is an approved drug, both are sold only as research chemicals, and GHRH analogs are banned in sport by WADA.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- These GH secretagogues are frequently combined to enhance growth hormone release.
Detailed Comparison
| Attribute | Ipamorelin | CJC-1295 (No DAC) |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place. | CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, the same receptor the body's own GHRH uses, prompting the pituitary to synthesize and release growth hormone. Native GHRH is broken down within minutes; CJC-1295 with DAC carries a reactive group that covalently bonds to circulating albumin after injection, shielding it from breakdown and stretching its half-life from minutes to days. The sustained GH elevation drives the liver to produce IGF-I, the downstream hormone behind many of GH's tissue effects. There are two versions: with DAC (long-acting, albumin-binding) and without DAC (Modified GRF 1-29), which lacks the albumin tether. Because it works through the pituitary, it relies on the gland's own GH-producing capacity. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks typical | 8-12 weeks |
| Best Time to Take | Before bed or morning (fasted) | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The foundational work is Raun et al. (1998) in the European Journal of Endocrinology, which characterized ipamorelin in rats, pigs and isolated pituitary cells and named it the first selective growth hormone secretagogue, releasing GH without raising ACTH or cortisol even at doses far above the GH-releasing dose. Most rigorous data is preclinical. In humans, the compound was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy. There are no large peer-reviewed human randomized controlled trials supporting the popular anti-aging, fat-loss, muscle-gain or recovery claims; those uses are extrapolations from the mechanism, not proven outcomes. Honestly stated: the receptor mechanism and GH-release effect are well documented, but human efficacy and long-term safety for wellness use are not established. | The key human study is Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism, a randomized, double-blind, placebo-controlled ascending-dose trial in healthy adults using the DAC version. A single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with cumulative effects on repeat dosing, and was reported as safe and relatively well tolerated short-term. A follow-up study in healthy men found GH still came in pulses rather than a flat line, with trough GH levels rising sharply. An earlier study showed once-daily CJC-1295 normalized growth in GHRH-knockout mice. These are hormone-level and pharmacokinetic studies, not outcome trials: there are no long-term human trials showing fat loss or muscle gain, and no published randomized trial of the popular CJC-1295 plus ipamorelin combination. The no-DAC form has essentially no published human data of its own. Development was halted after Phase II; a single trial death was attributed by the attending physician to pre-existing coronary artery disease rather than the drug, which is reported but not independently confirmed. FDA has also noted reported adverse events including increased heart rate and a systemic vasodilatory reaction. Bottom line: the GH and IGF-I-raising effect of the DAC version is well supported, while real-world efficacy and long-term safety are not. |
Frequently Asked Questions: Ipamorelin vs CJC-1295 (No DAC)
What is the difference between Ipamorelin and CJC-1295 (No DAC)?
Ipamorelin is a growth hormone peptide that ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by novo nordisk and derived from ghrp-1. it is researched mainly for stimulating the body's own growth hormone (gh) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. it is not an approved drug anywhere: it reached phase ii trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical. CJC-1295 (No DAC) is a growth hormone peptide that cjc-1295 is a synthetic analog of growth hormone-releasing hormone (ghrh), specifically a modified ghrh(1-29). the name covers two different products. cjc-1295 with dac (drug affinity complex) binds blood albumin, which stretches its half-life to roughly 6 to 8 days and raises gh and igf-i for days from a single injection; this is the version conjuchem took to phase ii before abandoning it, and the version the human data are about. cjc-1295 without dac (modified grf 1-29, the form this page is named for) lacks the albumin tether and is much shorter acting, though its human half-life has not been formally published. neither is an approved drug, both are sold only as research chemicals, and ghrh analogs are banned in sport by wada. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or CJC-1295 (No DAC)?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while CJC-1295 (No DAC) is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and CJC-1295 (No DAC) be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and CJC-1295 (No DAC) together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.